Press Releases

Company News
Summary ToggleAcura Pharmaceuticals Announces Successful Results from Study AP-LTX-301
Jan 08, 2018
*** LIMITx™ Product LTX-03 Advancing to IND ***

Read more

Summary ToggleAcura Pharmaceuticals Announces Third Quarter 2017 Financial Results
Nov 13, 2017
PALATINE, Ill. , Nov. 13, 2017 (GLOBE NEWSWIRE) -- Acura Pharmaceuticals, Inc. (OTCQB:ACUR), a specialty pharmaceutical company innovating abuse deterrent drugs, announced today financial results for the three and nine months ended September 30, 2017 .

Read more

Summary ToggleAcura Pharmaceuticals Advances LTX-03 and its LIMITx™ Technology
Oct 09, 2017
PALATINE, Ill. , Oct. 09, 2017 (GLOBE NEWSWIRE) -- Acura Pharmaceuticals, Inc. (OTCQB:ACUR), a specialty pharmaceutical company innovating abuse deterrent drugs , today announced that topline results from clinical study AP-LTX-300 (Study 300) for its LIMITx™ oral abuse deterrent drug LTX-03

Read more

Summary ToggleAcura Pharmaceuticals Presenting New LIMITx™ Clinical Data at the 19th Annual Rodman & Renshaw Conference
Sep 11, 2017
PALATINE, Ill. , Sept. 11, 2017 (GLOBE NEWSWIRE) -- Acura Pharmaceuticals, Inc. (OTCQB:ACUR), a specialty pharmaceutical company innovating abuse deterrent drugs , today announced the results from the previously undisclosed exploratory arm of its second LIMITx™ clinical study, study

Read more

Summary ToggleAcura Pharmaceuticals to Present at the 19th Annual RODMAN & RENSHAW Conference
Aug 31, 2017
PALATINE, Ill. , Aug. 31, 2017 (GLOBE NEWSWIRE) -- Acura Pharmaceuticals, Inc. (OTCQB:ACUR), a specialty pharmaceutical company innovating abuse deterrent drugs, today announced that Bob Jones , President and Chief Executive Officer, will present at the 19 th Annual Rodman & Renshaw Global

Read more

Summary ToggleAcura Pharmaceuticals Announces Second Quarter 2017 Financial Results
Aug 14, 2017
PALATINE, Ill. , Aug. 14, 2017 (GLOBE NEWSWIRE) -- Acura Pharmaceuticals, Inc. (OTCQB:ACUR), a specialty pharmaceutical company innovating abuse deterrent drugs, announced today financial results for the three and six months ended June 30, 2017 . The Company reported a net loss of $2.15 million or

Read more

Summary ToggleAcura Pharmaceuticals to Host Second Quarter 2017 Financial Results Conference Call on August 15, 2017
Aug 03, 2017
PALATINE, Ill. , Aug. 03, 2017 (GLOBE NEWSWIRE) -- Acura Pharmaceuticals, Inc. (OTCQB:ACUR), a specialty pharmaceutical company innovating abuse deterrent drugs , today announced that the Company plans to report financial results for the second quarter 2017 following the close of financial markets

Read more

Summary ToggleAcura Pharmaceuticals Raises $4.0 Million in a Private Placement
Jul 24, 2017

*** Provides Funding to Advance Development of Products Utilizing LIMITx™ Technology ***

Read more

Summary ToggleAcura Pharmaceuticals Advances LTX-04 and its LIMITx™ Technology
Jun 28, 2017

*** Peak blood levels of abused LIMITx doses can be reduced up to 65% ***

Read more

Summary ToggleAcura Pharmaceutical Initiates Second Clinical Study on LTX-04
May 18, 2017
PALATINE, Ill. , May 18, 2017 (GLOBE NEWSWIRE) -- Acura Pharmaceuticals, Inc. (NASDAQ:ACUR), a specialty pharmaceutical company innovating abuse deterrent drugs , today announced that the Company has completed enrollment and initiated dosing in a second Phase 1 human pharmacokinetic trial of

Read more

Summary ToggleAcura Pharmaceuticals Announces First Quarter 2017 Financial Results
May 12, 2017
PALATINE, Ill. , May 12, 2017 (GLOBE NEWSWIRE) -- Acura Pharmaceuticals, Inc. (NASDAQ:ACUR), a specialty pharmaceutical company innovating abuse deterrent drugs, announced today financial results for the first quarter ended March 31, 2017 . The Company reported net income of $0.4 million for the

Read more

Summary ToggleAcura Pharmaceuticals Announces Fourth Quarter 2016 and Full Year 2016 Financial Results
Mar 31, 2017
PALATINE, Ill. , March 31, 2017 (GLOBE NEWSWIRE) -- Acura Pharmaceuticals, Inc. (OTCQB:ACUR), a specialty pharmaceutical company innovating abuse deterrent drugs, announced today financial results for the year and three months ended December 31, 2016 .

Read more

Summary ToggleAcura Pharmaceuticals and MainPointe Pharmaceuticals Announce Deal for Nexafed® Products
Mar 17, 2017

Expands Commercialization of Acura's Methamphetamine-Resistant Pseudoephedrine Products

Read more

Summary ToggleAcura Pharmaceuticals Common Stock To Trade On The OTCQB Market
Feb 15, 2017
PALATINE, Ill. , Feb. 15, 2017 (GLOBE NEWSWIRE) -- Acura Pharmaceuticals, Inc. (NASDAQ:ACUR), a specialty pharmaceutical company innovating abuse deterrent drugs , today announced that shares of its common stock will begin to trade on the OTCQB® Market, which is operated by OTC Markets Group

Read more

Summary ToggleAcura Pharmaceuticals Exploring Strategic Alternatives
Jan 03, 2017

Roth Capital Engaged to Assist in the Process

Read more

Summary ToggleAcura Pharmaceutical Provides Development Update on its LIMITx(TM) Technology
Dec 14, 2016

FDA Provides Advice on Further Development of LTX-04

Read more

Summary ToggleAcura Pharmaceuticals Announces Third Quarter 2016 Financial Results
Nov 14, 2016
PALATINE, IL -- (Marketwired) -- 11/14/16 -- Acura Pharmaceuticals, Inc. ( NASDAQ : ACUR) , a specialty pharmaceutical company innovating abuse deterrent drugs, announced today financial results for the three and nine months ended September 30, 2016 .

Read more

Summary ToggleAcura Pharmaceuticals to Host Third Quarter 2016 Financial Results Conference Call on November 15, 2016
Nov 09, 2016
PALATINE, IL -- (Marketwired) -- 11/09/16 -- Acura Pharmaceuticals, Inc. ( NASDAQ : ACUR) , a specialty pharmaceutical company innovating abuse deterrent drugs , today announced that the Company plans to report financial results for the third quarter 2016 following the close of financial markets on

Read more

Displaying 19 - 36 of 151 results